Table 2 Comparative baseline characteristics of patients, stratified according to presence of high-risk features, treatments and IDC-P status
At least one high risk feature (n = 145) | No high-risk feature (n = 148) | |||||||
|---|---|---|---|---|---|---|---|---|
RP + ART, IDC-P[+] (n = 21) | RP + ART, IDC-P[−] (n = 27) | RP only, IDC-P[+] (n = 33) | RP only, IDC-P[−] (n = 64) | P * | RP only, IDC-P[+] (n = 19) | RP only, IDC-P[−] (n = 129) | P * | |
Mean age at diagnosis (S.D.) | 60.9 (5.8) | 62.1 (5.7) | 62.3 (6.5) | 61.7 (6.0) | 0.848 | 63.3 (8.1) | 62.1 (7.4) | 0.554 |
Grade Group | ||||||||
1 | 0 (0%) | 2 (7%) | 8 (24%) | 26 (41%) | < 0.001 | 8 (42%) | 85 (66%) | 0.134 |
2 | 7 (33%) | 15 (56%) | 10 (30%) | 31 (48%) | 9 (47%) | 36 (28%) | ||
3 | 8 (38%) | 7 (26%) | 11 (33%) | 4 (6%) | 2 (11%) | 8 (6%) | ||
4 | 1 (5%) | 0 (0%) | 1 (3%) | 1 (2%) | 0 | 0 | ||
5 | 5 (24%) | 3 (11%) | 3 (9%) | 2 (3%) | 0 | 0 | ||
Lymphovascular invasion | 12 (57%) | 9 (33%) | 6 (18%) | 7 (11%) | < 0.001 | 1 (5%) | 1 (1%) | 0.241 |
Extraprostatic extension | 20 (95%) | 23 (85%) | 22 (67%) | 43 (67%) | 0.026 | 0 | 0 | – |
Seminal vesicle invasion | 9 (43%) | 7 (26%) | 6 (18%) | 7 (11%) | 0.013 | 0 | 0 | – |
Positive margins | 12 (57%) | 16 (59%) | 17 (52%) | 35 (56%) | 0.942 | 0 | 0 | – |
Mean #of high-risk features (S.D.) | 2.2 (1.0) | 1.8 (0.8) | 1.5 (0.7) | 1.4 (0.6) | < 0.001 | 0 | 0 | – |
Median follow-up (months) (I.Q.R.) | 49 (30–67) | 44 (23–65) | 61 (24–123) | 108 (56–153) | < 0.001 | 89 (61–116) | 118 (84–139) | 0.685 |
Centre | ||||||||
1 | 19 (91%) | 20 (74%) | 0 | 0 | < 0.001 | 0 | 0 | – |
2 | 2 (9%) | 7 (26%) | 33 (100%) | 64 (100%) | 19 | 129 | ||